The Illinois Cannabis Regulation and Tax Act (“CRTA”), which was enacted in 2019, legalized recreational adult use cannabis in Illinois. The CRTA also created a Social Equity Program intended to offer disadvantaged people, communities of color, and those disproportionately impacted by the war on drugs an opportunity to benefit from the cannabis industry. Pursuant to the Social Equity Program, the Illinois Department of Agriculture (“IDOA”) awards points to applicants for cannabis licenses based on factors such as residing in an area disproportionately impacted by prior laws criminalizing cannabis and veteran status.[1] The program was widely praised and seen by many as a potential blueprint for other states. In practice, however, administration of the Social Equity Program has proved fraught with difficulties. Various types of applicants that have been denied the valuable licenses have sued IDOA, claiming that the department wrongfully denied their licenses.
About
Brad Graveline is a partner in the Intellectual Property and Litigation Practice Groups in the firm's Chicago office.
Latest Post
More Posts
Historic $130m+ Patent Infringement Award Against the United States of America
Historic $130m+ Patent Infringement Award Against the United States of America
What Do I Do With My Workplace Drug Policy Now That Cannabis Is Legal in Illinois and My Employees Are Remote?
What Do I Do With My Workplace Drug Policy Now That Cannabis Is Legal in Illinois and My Employees Are Remote?
Federal Circuit Agrees to Reconsider Ruling in GSK v. Teva Drug Patent Case
IMPACT OF COVID-19 ON ILLINOIS CANNABIS CONTRACTS — Do Force Majeure Clauses Provide A Defense To Non-Performance
IMPACT OF COVID-19 ON ILLINOIS CANNABIS CONTRACTS — Do Force Majeure Clauses Provide A Defense To Non-Performance
Defending Against Nonperformance Of Life Science Contracts
Supreme Court Holds that a Copyright Claimant May Commence an Infringement Suit Only After the Copyright Office Registers the Copyright
Supreme Court Holds that a Copyright Claimant May Commence an Infringement Suit Only After the Copyright Office Registers the Copyright
Suing The United States Government For Patent Infringement And Defending Against A Claim Of Obviousness
Proposed “Patent Agent Privilege” Promises Protection For Patent Practitioners And Clients
Proposed New FDA Labeling Rules Would Result in Increased Generic Drug Product Liability Claims
FTC v. Actavis: What Does It Mean for Reverse-Payment Settlements?
About
Brad Graveline is a partner in the Intellectual Property and Litigation Practice Groups in the firm's Chicago office.